Literature DB >> 21124077

Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.

Meera Nanjundan1, Lauren Averett Byers, Mark S Carey, Doris R Siwak, Maria Gabriela Raso, Lixia Diao, Jing Wang, Kevin R Coombes, Jack A Roth, Gordon B Mills, Ignacio I Wistuba, John D Minna, John V Heymach.   

Abstract

INTRODUCTION: The identification of key pathways dysregulated in non-small cell lung cancer (NSCLC) is an important step toward understanding lung pathogenesis and developing new therapeutic approaches.
METHODS: Toward this goal, reverse-phase protein lysate arrays (RPPA) were used to compare signaling pathways between NSCLC tumors and paired normal lung tissue from 46 patients and assess their association with clinical outcome.
RESULTS: After RPPA quantification of 63 proteins and phosphoproteins, tissue pairs were randomized to a training set (n = 25 pairs) and test set (n = 21 pairs). In the training set, 15 protein markers were differentially expressed between tumors and normal lung (p ≤ 0.01), including markers in the PI3K/AKT and p38 MAPK signaling pathways (e.g., p70S6K, S6, p38, and phospho-p38), as well as caveolin-1 and β-catenin. A four-protein signature (p70S6K, cyclin B1, pSrc(Y527), and caveolin-1) independent of histology classified specimens as tumor versus normal with a predicted accuracy of 83%, sensitivity of 67%, and specificity of 100%. The signature was validated in the test set, correctly classifying all normal tissues and 14 of 21 tumor tissues. RPPA results were confirmed by immunohistochemistry for caveolin-1 and p70S6K. In tumors from patients with resected NSCLC, expression of proteins in the energy-sensing AMPK pathway (pLKB1, AMPK, p-Acetyl-CoA, pTSC2), adhesion, EGFR, and Rb signaling pathways was inversely associated with NSCLC recurrence.
CONCLUSIONS: These data provide evidence for dysregulation of several pathways including those involving energy sensing and adhesion that are potentially associated with NSCLC pathogenesis and disease recurrence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21124077      PMCID: PMC3374718          DOI: 10.1097/JTO.0b013e3181f2a266

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  30 in total

1.  Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values.

Authors:  Stan Pounds; Stephan W Morris
Journal:  Bioinformatics       Date:  2003-07-01       Impact factor: 6.937

2.  Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma.

Authors:  Hirokazu Awaya; Yukio Takeshima; Vishwa Jeet Amatya; Hajime Ishida; Masahiro Yamasaki; Nobuoki Kohno; Kouki Inai
Journal:  Pathol Int       Date:  2005-01       Impact factor: 2.534

3.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

Review 4.  Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Authors:  Katherine M Sheehan; Valerie S Calvert; Elaine W Kay; Yiling Lu; David Fishman; Virginia Espina; Joy Aquino; Runa Speer; Robyn Araujo; Gordon B Mills; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  Mol Cell Proteomics       Date:  2005-01-25       Impact factor: 5.911

5.  Reduction of caveolin 1 gene expression in lung carcinoma cell lines.

Authors:  C Racine; M Bélanger; H Hirabayashi; M Boucher; J Chakir; J Couet
Journal:  Biochem Biophys Res Commun       Date:  1999-02-24       Impact factor: 3.575

6.  Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.

Authors:  Tien Hoang; Ronghui Xu; Joan H Schiller; Philip Bonomi; David H Johnson
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

7.  Difference of caveolin-1 expression pattern in human lung neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma and squamous cell carcinoma.

Authors:  Tatsuya Kato; Masaki Miyamoto; Kentaro Kato; Yasushi Cho; Tomoo Itoh; Toshiaki Morikawa; Shunichi Okushiba; Satoshi Kondo; Toshiro Ohbuchi; Hiroyuki Katoh
Journal:  Cancer Lett       Date:  2004-10-08       Impact factor: 8.679

8.  Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry.

Authors:  George Deeb; Jianmin Wang; Nithya Ramnath; Harry K Slocum; Sam Wiseman; Amy Beck; Dongfeng Tan
Journal:  Mod Pathol       Date:  2004-04       Impact factor: 7.842

9.  Proteomic patterns of tumour subsets in non-small-cell lung cancer.

Authors:  Kiyoshi Yanagisawa; Yu Shyr; Baogang J Xu; Pierre P Massion; Paul H Larsen; Bill C White; John R Roberts; Mary Edgerton; Adriana Gonzalez; Sorena Nadaf; Jason H Moore; Richard M Caprioli; David P Carbone
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

10.  Assay of Rab25 function in ovarian and breast cancers.

Authors:  Kwai Wa Cheng; Yiling Lu; Gordon B Mills
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

View more
  25 in total

1.  Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Authors:  Yanyan Lou; Lixia Diao; Edwin Roger Parra Cuentas; Warren L Denning; Limo Chen; You Hong Fan; Lauren A Byers; Jing Wang; Vassiliki A Papadimitrakopoulou; Carmen Behrens; Jaime Canales Rodriguez; Patrick Hwu; Ignacio I Wistuba; John V Heymach; Don L Gibbons
Journal:  Clin Cancer Res       Date:  2016-02-05       Impact factor: 12.531

Review 2.  Proteomics and biomarkers in clinical trials for drug development.

Authors:  Jung-min Lee; Jasmine J Han; Gary Altwerger; Elise C Kohn
Journal:  J Proteomics       Date:  2011-05-04       Impact factor: 4.044

3.  Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.

Authors:  Krit Ritthipichai; Cara L Haymaker; Melisa Martinez; Andrew Aschenbrenner; Xiaohui Yi; Minying Zhang; Charuta Kale; Luis M Vence; Jason Roszik; Yared Hailemichael; Willem W Overwijk; Navin Varadarajan; Roza Nurieva; Laszlo G Radvanyi; Patrick Hwu; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

4.  Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.

Authors:  Robert J Cardnell; Ying Feng; Lixia Diao; You-Hong Fan; Fatemah Masrorpour; Jing Wang; Yuqiao Shen; Gordon B Mills; John D Minna; John V Heymach; Lauren A Byers
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

5.  Three-Dimensionally Functionalized Reverse Phase Glycoprotein Array for Cancer Biomarker Discovery and Validation.

Authors:  Li Pan; Hillary Andaluz Aguilar; Linna Wang; Anton Iliuk; W Andy Tao
Journal:  J Am Chem Soc       Date:  2016-11-17       Impact factor: 15.419

Review 6.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07

7.  Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.

Authors:  Monique B Nilsson; Huiying Sun; Lixia Diao; Pan Tong; Diane Liu; Lerong Li; Youhong Fan; Alissa Poteete; Seung-Oe Lim; Kathryn Howells; Vincent Haddad; Daniel Gomez; Hai Tran; Guillermo Armaiz Pena; Lecia V Sequist; James C Yang; Jing Wang; Edward S Kim; Roy Herbst; J Jack Lee; Waun Ki Hong; Ignacio Wistuba; Mien-Chie Hung; Anil K Sood; John V Heymach
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

8.  A pilot characterization of human lung NSCLC by protein pathway activation mapping.

Authors:  Angela Zupa; Giuseppina Improta; Alessandra Silvestri; Elisa Pin; Jianghong Deng; Michele Aieta; Pellegrino Musto; Donato Nitti; Enzo Mammano; Lance Liotta; Claudio Belluco; Julia Wulfkuhle; Emanuel Petricoin
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

9.  Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays.

Authors:  T S Gujral; R L Karp; A Finski; M Chan; P E Schwartz; G MacBeath; P Sorger
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

10.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.